NatureCell FY 2025 Annual ReportBeta
NatureCell annual report for FY 2025, filed with DART (Korea Financial Supervisory Service) on March 23, 2026. This page provides AI-powered English analysis including business overview, management discussion & analysis (MD&A), risk factors, and KIFRS consolidated financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE).
NatureCell FY 2025 Annual Report Analysis
Business Overview
- • Stem cell business 57% and food business 41% share of KRW 20.7B revenue in FY2025
- • JointStem osteoarthritis treatment received US FDA Breakthrough Therapy designation Mar 2025 and Expanded Access Program approval Jun 2025
Management Discussion & Analysis
- • Revenue KRW 20.7B (-35.8% YoY), Operating loss KRW 3.6B vs. operating profit KRW 59M prior year
- • Stem cell segment revenue KRW 11.9B, operating loss KRW 2.4B; decline due to culture media system upgrade and schedule adjustment
Risk Factors
- • Overseas raw material imports expose currency risk; no quantified KRW impact disclosed
- • No derivative transactions currently outstanding; no past derivative activity reported
NatureCell FY 2025 Key Financial MetricsDART
Total Assets
KRW 74.7B
▲ +3.8% YoY
Operating Cash Flow
KRW 156.7M
▼ -89.6% YoY
CapEx
KRW 16.5B
▲ +433.0% YoY
Source: KIFRS consolidated financial data from NatureCell annual report on DART. All figures in KRW.
Source: DART (Korea Financial Supervisory Service) · AI summaries generated from the original Korean filing (English output) · Beta: coverage is expanding